Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]

Phase III study finds initial nivolumab-based treatment halts melanoma...

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase III study finds initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Extensive lymph node surgery may not be necessary for some patients with...

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Extensive lymph node surgery may not be necessary for some patients with melanoma ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

Extensive lymph node surgery may not be necessary for some patients with...

Prof Claus Garbe - University of Tübingen, Tübingen, Germany.

Extensive lymph node surgery may not be necessary for some patients with melanoma ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany. )

Comment: Research developments stir hopes for melanoma

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Research developments stir hopes for melanoma ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced...

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

New immunotherapy yields long-lasting responses in some patients with advanced...

Dr Mark Middleton - University of Oxford, Oxford, UK

New immunotherapy yields long-lasting responses in some patients with advanced melanoma ( Dr Mark Middleton - University of Oxford, Oxford, UK )

Investigational immunotherapy drug combo safe with early signs of effectiveness...

Dr David Bajor - University of Pennsylvania, Philadelphia, USA

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma ( Dr David Bajor - University of Pennsylvania, Philadelphia, USA )

Chk1 inhibition combined with standard dose gemcitabine may be safe and...

Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )

More from ecancer